Supportive Care in Cancer

, 18:179 | Cite as

Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA

  • Debra L. BartonEmail author
  • Gamini S. Soori
  • Brent A. Bauer
  • Jeff A. Sloan
  • Patricia A. Johnson
  • Cesar Figueras
  • Steven Duane
  • Bassam Mattar
  • Heshan Liu
  • Pamela J. Atherton
  • Bradley Christensen
  • Charles L. Loprinzi
Original Article



This pilot trial sought to investigate whether any of three doses of American ginseng (Panax quinquefolius) might help cancer-related fatigue. A secondary aim was to evaluate toxicity.


Eligible adults with cancer were randomized in a double-blind manner, to receive American ginseng in doses of 750, 1,000, or 2,000 mg/day or placebo given in twice daily dosing over 8 weeks. Outcome measures included the Brief Fatigue Inventory, vitality subscale of the Medical Outcome Scale Short Form-36 (SF-36), and the Global Impression of Benefit Scale at 4 and 8 weeks.


Two hundred ninety patients were accrued to this trial. Nonsignificant trends for all outcomes were seen in favor of the 1,000- and 2,000-mg/day doses of American ginseng. Area under the curve analysis of activity interference from the Brief Fatigue Inventory was 460–467 in the placebo group and 750 mg/day group versus 480–551 in the 1,000- and 2,000-mg/day arms, respectively. Change from baseline in the vitality subscale of the SF-36 was 7.3–7.8 in the placebo and the 750-mg/day arm, versus 10.5–14.6 in the 1,000- and 2,000-mg/day arms. Over twice as many patients on ginseng perceived a benefit and were satisfied with treatment over those on placebo. There were no significant differences in any measured toxicities between any of the arms.


There appears to be some activity and tolerable toxicity at 1,000–2,000 mg/day doses of American ginseng with regard to cancer-related fatigue. Thus, further study of American ginseng is warranted.


Panax quinquefolius American ginseng Cancer-related fatigue  Botanicals 


  1. 1.
    NCCN Cancer Related Fatigue Clinical Practice Guidelines in Oncology V.1.2003.
  2. 2.
    Mock V (2001) Fatigue management, evidence and guidelines for practice. Cancer 92(6):1699–1707. doi: 10.1002/1097-0142(20010915) 92:6+<1699::AID-CNCR1500>3.0.CO;2-9 CrossRefPubMedGoogle Scholar
  3. 3.
    Fulton C, Knowles G (2000) Cancer fatigue. Eur J Cancer Care (Engl) 9(3):167–171Google Scholar
  4. 4.
    Gutstein HB (2001) The biological basis of fatigue. Cancer 92(6):1678–1683. doi: 10.1002/1097-0142(20010915) 92:6+<1678::AID-CNCR1496>3.0.CO;2-R CrossRefPubMedGoogle Scholar
  5. 5.
    Berger AM, Farr LA, Kuhn BR, Fischer P, Agrawal S (2007) Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manage 33(4):398–409. doi: 10.1016/j.jpainsymman.2006.09.022 CrossRefPubMedGoogle Scholar
  6. 6.
    Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J (2004) Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 32:40–50. doi: 10.1093/jncimonographs/lgh027 CrossRefPubMedGoogle Scholar
  7. 7.
    Bower JE, Ganz PA, Desmond KA, Rowland KA, Meyerowitz JH, Belin BE, Thomas R (2000) Fatigue in breast cancer survivors: occurrences, correlates, and impact on quality of life. J Clin Oncol 18:743–753PubMedGoogle Scholar
  8. 8.
    Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, Belin TR (2006) Fatigue in long-term breast carcinoma survivors. A longitudinal investigation. Cancer 106:751–758. doi: 10.1002/cncr.21671 CrossRefPubMedGoogle Scholar
  9. 9.
    Baker F, Denniston M, Smith T, West MM (2005) Adult cancer survivors: how are they faring. Cancer 104(Suppl 11):2565–2576. doi: 10.1002/cncr.21488 CrossRefPubMedGoogle Scholar
  10. 10.
    Mitchell SA, Beck SL, Edward Hood L, Moore K, Tanner ER (2007) Putting evidence into practice: evidence-based interventions of fatigue during and following cancer and its treatment. Clin J Oncol Nurs 11(1):99–113. doi: 10.1188/07.CJON.99-113 CrossRefPubMedGoogle Scholar
  11. 11.
    Mitchell SA, Berger AM (2006) Cancer-related fatigue: the evidence base for assessment and management. Cancer J 12:374–387. doi: 10.1097/00130404-200609000-00007 CrossRefPubMedGoogle Scholar
  12. 12.
    Mock V, Pickett M, Ropka M, Lin E, Grimm P, Rhodes V, McDaniel R, Grimm PM, Krumm S, McCorkle R (2001) Fatigue, physical functioning, emotional distress, and quality of life outcomes of a walking intervention during breast cancer treatment. Cancer Pract 9:119–127. doi: 10.1046/j.1523-5394.2001.009003119.x CrossRefPubMedGoogle Scholar
  13. 13.
    Schwartz AL, Mori M, Gao R, Nail R, King LM, Marjorie E (2001) Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc 33:718–723. doi: 10.1097/00005768-200105000-00006 CrossRefPubMedGoogle Scholar
  14. 14.
    Stone P, Richards M, Hardy J (1998) Fatigue in patients with cancer. Eur J Cancer 34(11):1670–1676. doi: 10.1016/S0959-8049(98)00167-1 CrossRefPubMedGoogle Scholar
  15. 15.
    Portenoy RK, Itri LM (1999) Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4:1–10PubMedGoogle Scholar
  16. 16.
    Burks TF (2001) New agents for the treatment of cancer-related fatigue. Cancer 92(Suppl 6):1714–1718. doi: 10.1002/1097-0142(20010915)92:6+<1714::AID-CNCR1502>3.0.CO;2-N CrossRefPubMedGoogle Scholar
  17. 17.
    Bruera E, Driver L, Barnes EA, Willey J, Shen L, Palmer JL, Escalante C (2003) Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 21(23):4439–4443. doi: 10.1200/JCO.2003.06.156 CrossRefPubMedGoogle Scholar
  18. 18.
    Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, Palmer JL (2006) Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 24(13):2073–2078. doi: 10.1200/JCO.2005.02.8506 CrossRefPubMedGoogle Scholar
  19. 19.
    Bruera E, Osta E, Vlaero V, Driver L, Palmer J, Pei B, Shen L, Poulter V (2007) Donepezil for cancer-related fatigue: a double-blind, randomized, placebo-controlled study. J Clin Oncol 25(23):3475–3481, Part I II 493s(9003)CrossRefPubMedGoogle Scholar
  20. 20.
    Stankoff B, Waubant E, Confavreau C, Edan G, Debouverie M, Rumback L, Moreau Tl, Pelletier J, Lubetzki C, Clanet M, French Modafinil Study Group (2005) Modafinil for fatigue in MS: a randomized placebo-controlled double blind study. Neurology 64:1139–1143PubMedGoogle Scholar
  21. 21.
    Attele AS, Wu JA, Yuan C (1999) Ginseng pharmacology. Biochem Pharmacol 58:1685–1693. doi: 10.1016/S0006-2952(99)00212-9 CrossRefPubMedGoogle Scholar
  22. 22.
    Ginseng (American ginseng, Asian ginseng, Chinese ginseng, Korean red ginseng, Panax ginseng: Panax spp. Including P. ginseng C.C. Meyer and P. quinquefolius L., excluding Eleutherococcus senticosus). Accessed on 4 April 2007
  23. 23.
    Cui J (1995) Identification and quantification of ginsenosides in various commercial ginseng preparations. Eur J Pharm Sci 3:77–85. doi: 10.1016/0928-0987(94)00077-D CrossRefGoogle Scholar
  24. 24.
    Tadano T, Nakagawasai O, Niijima F, Tan-No K, Kisara K (2000) The effects of traditional tonics on fatigue in mice differ from those of the antidepressant imipramine: a pharmacological and behavioral study. Am J Chin Med 28(1):97–104. doi: 10.1142/S0192415X0000012X CrossRefPubMedGoogle Scholar
  25. 25.
    Banerjee U, Izquierdo JA (1982) Antistress and antifatigue properties of Panax ginseng: comparison with piracetam. Acta Physiol Lat Am 32(4):277–285PubMedGoogle Scholar
  26. 26.
    Marasco CA, Ruiz VR, Villagomex SA, Infante BC (1996) Double-blind study of a multivitamin complex supplemented with ginseng extract. Drugs Exp Clin Res XXII 6:323–329Google Scholar
  27. 27.
    Younus J, Collins A, Wang X, Saunders M, Manuel J, Freake C, Defen P (2003) A double blind placebo controlled pilot study to evaluate the effect of ginseng on fatigue and quality of life in adult chemo-naïve cancer patients. J Clin Oncol 22:733, abstract # 2947Google Scholar
  28. 28.
    Asafu-Adjaye EB, Wong SK (2003) Determination of ginsenosides (ginseng saponins) in dry root powder from Panax ginseng, Panax quinquefolius, and selected commercial products by liquid chromatography: interlaboratory study. J AOAC Int 86(6):1112–1123PubMedGoogle Scholar
  29. 29.
    Wang X, Sakuma T, Asafu-Adjaye E, Shiu GK (1999) Determination of ginsenosides in plant extracts from Panax ginseng and Panax quinquefolius L. by LC/MS/MS. Anal Chem 8:1579–1584. doi: 10.1021/ac980890p CrossRefGoogle Scholar
  30. 30.
    Xie JT, Maleckar SA, Yuan CS (2003) Is ginseng free from adverse effects? In: Yuan CS, Bieber E (eds) Complementary and alternative medicine, chapter 17. CRC, Boca RatonGoogle Scholar
  31. 31.
    Wang LC, Lee TF (1998) Effect of ginseng saponins on exercise performance in non-trained rats. Planta Med 64(2):130–133. doi: 10.1055/s-2006-957389 CrossRefPubMedGoogle Scholar
  32. 32.
    Vuksan V, Sievenpiper JL, Koo VY, Francis T, Beljan-Zdravkovic U, Xu Z, Vidgen E (2000) American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med 160(7):1009–1013. doi: 10.1001/archinte.160.7.1009 CrossRefPubMedGoogle Scholar
  33. 33.
    Sotaniemi EA, Haapakoski E, Rautio A (1995) Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 18(10):1373–1375. doi: 10.2337/diacare.18.10.1373 CrossRefPubMedGoogle Scholar
  34. 34.
    King ML, Adler SR, Murphy LL (2006) Extraction-dependent effects of American ginseng (Panax quinquefolium) on human breast cancer cell proliferation and estrogen receptor activation. Integr Cancer Ther 5(3):236–243. doi: 10.1177/1534735406291341 CrossRefPubMedGoogle Scholar
  35. 35.
    King ML, Murphy LL (2007) American ginseng (Panax quinquefolius L.) extract alters mitogen-activated protein kinase cell signaling and inhibits proliferation of MCF-7 cells. J Exp Ther Oncol 6:147–155PubMedGoogle Scholar
  36. 36.
    Duda RB, Zhong Y, Navas V, Li MZ, Toy BR, Alavarez JG (1999) American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol 72(4):230–239. doi: 10.1002/(SICI) 1096-9098(199912) 72:4<230::AID-JSO9>3.0.CO;2-2 CrossRefPubMedGoogle Scholar
  37. 37.
    Bahrke MS, Morgan WR (2000) Evaluation of the ergogenic properties of ginseng: an update. Sports Med 29(2):113–133. doi: 10.2165/00007256-200029020-00004 CrossRefPubMedGoogle Scholar
  38. 38.
    Ginseng Board of Wisconsin. Last accessed November 2007
  39. 39.
    Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patient’s use of the Brief Fatigue Inventory. Cancer 85:1186–1196. doi: 10.1002/(SICI) 1097-0142(19990301) 85:5<1186::AID-CNCR24>3.0.CO;2-N CrossRefPubMedGoogle Scholar
  40. 40.
    Ware JE, Sherbourne CD (1992) The MOS 36-Item Short-Form Health Survey (SF-36). Conceptual framework and item selection. Med Care 30(6):473–481. doi: 10.1097/00005650-199206000-00002 CrossRefPubMedGoogle Scholar
  41. 41.
    Buysse D, Reynolds C, Monk T, Berman S, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213. doi: 10.1016/0165-1781(89)90047-4 CrossRefPubMedGoogle Scholar
  42. 42.
    Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, Sloan JA, Clinical Significance Consensus Meeting Group (2002) Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77:371–383. doi: 10.4065/77.4.371 CrossRefPubMedGoogle Scholar
  43. 43.
    Hyland ME, Sodergren SC (1996) Development of a new type of global quality of life scale and comparison and preference for 12 global scales. Qual Life Res 5(5):469–480. doi: 10.1007/BF00540019 CrossRefPubMedGoogle Scholar
  44. 44.
    Sloan A, O’Fallon JR, Suman VJ (1998) Incorporating quality of life measurement into oncology clinical trials. Proc Am Stat Assoc, pp 282–287Google Scholar
  45. 45.
    Wewers ME, Lowe NK (1990) A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 13:227–236. doi: 10.1002/nur.4770130405 CrossRefPubMedGoogle Scholar
  46. 46.
    Grunberg SM, Groshen S, Steingass S, Zaretsky S, Meyerowitz B (1996) Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res 5:65–72. doi: 10.1007/BF00435970 CrossRefPubMedGoogle Scholar
  47. 47.
    Cohen J (1988) Statistical power analysis for the behavioral sciences. Erlbaum, Hillsdale, NJGoogle Scholar
  48. 48.
    Lipsitz SR, Fitzmaurice GM, Orav EJ, Laird NM (1994) Performance of generalized estimating equations in practical situations. Biometrics 50:270–278. doi: 10.2307/2533218 CrossRefPubMedGoogle Scholar
  49. 49.
    Sievenpiper JL, Arnason JT, Leiter LA, Vuksan V (2003) Variable effects of American ginseng: a batch of American ginseng (Panax quinquefolius L.) with a depressed ginsenoside profile does not affect postprandial glycemia. Eur J Clin Nutr 57(2):243–248. doi: 10.1038/sj.ejcn.1601550 CrossRefPubMedGoogle Scholar
  50. 50.
    Yuan C, Attele AS, Wu JA, Liu D (1998) Modulation of American ginseng on brainstem GABAergic effects in rats. J Ethnopharmacol 62:215–222. doi: 10.1016/S0378-8741(98)00066-X CrossRefPubMedGoogle Scholar
  51. 51.
    Lian XY, Zhang Z, Stringer JL (2005) Protective effects of ginseng components in a rodent model of neurodegeneration. Ann Neurol 57(5):642–648. doi: 10.1002/ana.20450 CrossRefPubMedGoogle Scholar

Copyright information

© US Government 2009

Authors and Affiliations

  • Debra L. Barton
    • 1
    Email author
  • Gamini S. Soori
    • 2
  • Brent A. Bauer
    • 1
  • Jeff A. Sloan
    • 1
  • Patricia A. Johnson
    • 3
  • Cesar Figueras
    • 4
  • Steven Duane
    • 5
  • Bassam Mattar
    • 6
  • Heshan Liu
    • 1
  • Pamela J. Atherton
    • 1
  • Bradley Christensen
    • 1
  • Charles L. Loprinzi
    • 1
  1. 1.Mayo Clinic and Mayo FoundationRochesterUSA
  2. 2.Missouri Valley Cancer ConsortiumOmahaUSA
  3. 3.Carle Cancer Center CCOPUrbanaUSA
  4. 4.Michigan Cancer Research ConsortiumAnn ArborUSA
  5. 5.Metro-Minnesota Community Clinical Oncology ProgramSt. Louis ParkUSA
  6. 6.Wichita Community Clinical Oncology ProgramWichitaUSA

Personalised recommendations